Aytu is committed to improving the health of all children. We’re developing a portfolio of products to help children be their best by addressing significant conditions that affect children and their families every day. Our adult and consumer health products remain an important part of our heritage, while we study potential COVID-19 treatments and are now investing in potential breakthroughs for rare diseases. Follow us on our journey.
Decades of experience with a focus on better health today.
The Aytu BioPharma leadership team is as unique as our portfolio of products. Our experience spans decades, but we never stop thinking about the future.
Chairman & Chief Executive Officer
Chief Financial Officer
Chief Commercial Officer
Executive Vice President, Rare Disease Operations
Executive Vice President, Rare Disease Development
Senior Vice President of Research & Development
Vice President of Operations
Vice President of Regulatory Affairs and Quality Assurance
Board of Directors
Chairman & Chief Executive Officer
John Donofrio, Jr.
Director, Chair, Audit Committee
Director & Chair, Nominating & Governance Committee
Director, Chair, Compensation Committee
Our Mission & Vision
We aspire to be the leading pediatric-focused pharmaceutical company in the world. We will achieve this by commercializing novel therapeutics, providing best-in-class patient access, unleashing the talents of our people, and developing important and needed therapeutics for children of all ages.
- We will make a lasting difference in children’s lives by delivering the best products to children in need.
- Our individual actions, collective attitude, and company results will inspire others to do great things.
- Our people, products, pipeline, and platform will effect positive change in healthcare delivery and patient outcomes.
Supporting our Communities
At Aytu we strive to make a positive impact on children through our product offerings, the development of our innovative pipeline, and the actions of our outstanding people. We are active in our communities and support the work of various organizations that work on behalf of the patients we aim to serve, the children in our communities, and our corporate ecosystem.
We are a corporate partner to several leading patient advocacy organizations supporting Vascular Ehlers-Danlos Syndrome (VEDS) patients and their caregivers. We are engaged with and support Annabelle’s Challenge, The Ehlers-Danlos Society, FIGHT vEDS, and The VEDS Movement. We are also corporate sponsors of each organization’s programs.
Annabelle’s Challenge is the leading charity providing support to patients and families touched by Vascular Ehlers-Danlos Syndrome (Vascular EDS) across the UK and globally. They are also proud recipients of The Queen’s Award for Voluntary Service.
The Ehlers-Danlos Society is dedicated to saving and improving the lives of those affected worldwide by the Ehlers-Danlos syndromes (EDS), hypermobility spectrum disorders (HSD), and related symptoms and conditions.
FIGHT vEDS is a non-profit organization dedicated to fighting and finding a treatment for vascular Ehlers-Danlos Syndrome. Their three core initiatives include bringing up-to-date information to patients, promoting low-cost genetic testing, and advancing research.
The VEDS Movement mission is to save lives and improve the quality of life of individuals with Vascular Ehlers-Danlos Syndrome (VEDS).
Aytu BioPharma is also a corporate sponsor of a Colorado-based not-for-profit focused on improving the lives of children and families in Colorado. We also encourage our team members to influence positive change through their personal actions, professional work and volunteerism in their communities.
We are active in the Colorado life sciences and biotechnology ecosystem and are corporate members of the Colorado BioScience Association. We actively advocate for and support the work of our life science corporate neighbors.